The agency’s decision on Eisai and Biogen’s newly approved drug contrasts with a stringent Medicare policy that limits coverage to only patients in clinical trials.
The agency’s decision on Eisai and Biogen’s newly approved drug contrasts with a stringent Medicare policy that limits coverage to only patients in clinical trials.